UNICYCIVE THERAPEUTICS
Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’s Syndrome and by addressing the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease. Unicycive Therapeutics was founded in 2016 and is headquartered in Los Altos, California.
UNICYCIVE THERAPEUTICS
Industry:
Biotechnology Health Care Health Diagnostics Medical
Founded:
2016-01-01
Address:
Los Altos, California, United States
Country:
United States
Website Url:
http://www.unicycive.com
Total Employee:
11+
Status:
Active
Contact:
(650) 384-0642
Total Funding:
86.6 M USD
Technology used in webpage:
Amazon HSTS Amazon Virginia Region CloudFront PostalAddress Schema Amazon S3 COVID-19 Amazon S3 CDN Vimeo Corporation Schema
Similar Organizations
ArtisanBio
ArtisanBio is provider of cell engineering and data analysis solutions that advance the cell therapy revolution.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Thrive Earlier Detection
Thrive Earlier Detection is a healthcare company that integrates earlier cancer detection into routine medical care.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Great Point Partners
Great Point Partners investment in Post-IPO Equity - Unicycive Therapeutics
Velan Capital
Velan Capital investment in Post-IPO Equity - Unicycive Therapeutics
Vivo Capital
Vivo Capital investment in Post-IPO Equity - Unicycive Therapeutics
Octagon Capital Advisors
Octagon Capital Advisors investment in Post-IPO Equity - Unicycive Therapeutics
Logos Capital
Logos Capital investment in Post-IPO Equity - Unicycive Therapeutics
SilverArc Capital
SilverArc Capital investment in Post-IPO Equity - Unicycive Therapeutics
Walleye Capital
Walleye Capital investment in Post-IPO Equity - Unicycive Therapeutics
Nantahala Capital Management
Nantahala Capital Management investment in Post-IPO Equity - Unicycive Therapeutics
Logos Capital
Logos Capital investment in Post-IPO Equity - Unicycive Therapeutics
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Unicycive Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-26 | Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy |
Official Site Inspections
http://www.unicycive.com Semrush global rank: 5.21 M Semrush visits lastest month: 1.49 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Unicycive Therapeutics"
Company - Unicycive
UNICYCIVE was founded in August 2016 by Shalabh Gupta, MD, with the goal of building a company to solve the most pressing unmet medical needs in renal diseases. In 2018, Dr. …See details»
Unicycive Therapeutics - Crunchbase Company Profile & Funding
Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease …See details»
Unicycive Therapeutics - LinkedIn
Unicycive Therapeutics Biotechnology Research Los Altos, CA 1,667 followers Unicycive Therapeutics empowers kidney doctors to address the medical needs of their patients.See details»
Investor Relations :: Unicycive Therapeutics, Inc. (UNCY)
Nov 11, 2024 Unicycive Therapeutics, Inc. 4300 El Camino Real Suite 210 Los Altos, CA 94022 T: 650-351-4495 [email protected]. Investor Relations. T: 650-543-5470 [email protected]. Transfer Agent. Philadelphia Stock Transfer, …See details»
Unicycive Therapeutics Announces U.S. FDA Acceptance of the …
Nov 11, 2024 Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a …See details»
Shalabh Gupta, MD - Unicycive
Dr. Shalabh Gupta, MD, founder, chairman of the board of directors and CEO of Unicycive Therapeutics Inc. Shalabh Gupta, MD, is the founder of Unicycive and has served as Chief Executive Officer, President, and director since August …See details»
Unicycive Therapeutics Issues Shareholder Letter to Highlight …
Jan 23, 2024 Unicycive Therapeutics, Inc. – Topline Data from OLC Pivotal Trial Expected in Q2 2024 – – OLC will target the multibillion-dollar hyperphosphatemia market –See details»
Unicycive to Showcase Pipeline of Innovative Product …
Oct 26, 2022 Unicycive has completed a clinical trial studying Renazorb in 32 healthy volunteers. In this study Renazorb was minimally absorbed to the systemic circulation and was safe and well-tolerated at doses up to 6000 …See details»
Unicycive Announces up to $130 Million Financing to …
Mar 6, 2023 Unicycive Therapeutics, Inc. $30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones. Led by Vivo Capital with participation from RA …See details»
Unicycive Therapeutics Announces Initial Positive Patient ... - Nasdaq
Jul 10, 2024 Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a …See details»
Therapeutic Focus - Unicycive
Why Dr. Glenn Chertow believes in Unicycive. A renowned nephrology expert, discusses the pioneering work of Unicycive Therapeutics in the treatment of kidney disease. Dr. Chertow …See details»
Unicycive Therapeutics, Inc. (UNCY) - Yahoo Finance
Find the latest Unicycive Therapeutics, Inc. (UNCY) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Unicycive Announces Second Quarter 2023 Financial Results and …
LOS ALTOS, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company …See details»
Unicycive Therapeutics, Inc. (UNCY) - Stock Analysis
5 days ago About UNCY. Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI …See details»
Unicycive Therapeutics, Inc. (UNCY) - Yahoo Finance Canada
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil …See details»
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical …
Mar 7, 2024 Topline Data Expected in Q2, 2024LOS ALTOS, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology …See details»
Unicycive Announces Full Year 2021 Financial Results and Provides ...
Mar 31, 2022 Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new …See details»
Pipeline - Unicycive
Program. OLC. UNI-494. UNI-494. Indication. Hyperphosphatemia. Acute Kidney Injury (AKI) Chronic Kidney Disease (CKD) 505b(2) Healthy volunteer BE study completed Phase 1 (in the …See details»
Breakeven On The Horizon For Unicycive Therapeutics, Inc.
2 days ago Unicycive Therapeutics is bordering on breakeven, according to the 6 American Biotechs analysts. They anticipate the company to incur a final loss in 2025, before generating …See details»